Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology

Hui, Pei

doi:10.5858/arpa.2018-0234-ra

Cited by 72 publications

(70 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hemorrhagic focus can be found in PSTT. There is hardly normal villus structure under microscopic observation (58, 59). In addition, there are abundant intermediate trophoblasts, but no cytotrophoblasts or syncytiotrophoblasts (58).…”

Section: Clinical Presentationmentioning

confidence: 99%

“…There is hardly normal villus structure under microscopic observation (58, 59). In addition, there are abundant intermediate trophoblasts, but no cytotrophoblasts or syncytiotrophoblasts (58). PSTT tumor cells infiltrate into the uterine myometrium in a strip-like manner, revealing the invasive ability of the intermediate trophoblasts at the implantation site.…”

Section: Clinical Presentationmentioning

confidence: 99%

“…PSTT tumor cells infiltrate into the uterine myometrium in a strip-like manner, revealing the invasive ability of the intermediate trophoblasts at the implantation site. PSTT invades deep myometrium of the uterus and extends to serosa in some cases (58). The mitotic figures of PSTT vary.…”

Section: Clinical Presentationmentioning

confidence: 99%

See 2 more Smart Citations

A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors

et al. 2019

View full text Add to dashboard Cite

Placental site trophoblastic tumor (PSTT) is a rare type of gestational trophoblastic disease originating from the intermediate trophoblast. Compared with hydatidiform mole, invasive hydatidiform mole and choriocarcinoma, the diagnosis of PSTT is more complicated and lacks specific and sensitive tumor markers. Most PSTT patients demonstrate malignant potential, and the primary treatment of PSTT is hysterectomy. However, metastasis occasionally occurs and even causes death in a small number of PSTT patients. Most PSTT patients are young women hence fertility preservation is an important consideration. The major obstacle for PSTT patient prognosis is chemotherapy resistance. However, the current understanding of the pathogenesis of PSTT and clinical treatment remains elusive. In this review, we summarized the research progress of PSTT in recent years from three aspects: mechanism, clinical presentation, and treatment and prognosis. Well-conducted multi-center studies with sufficient sample sizes are of great importance to better examine the pathological progress and evaluate the prognosis of PSTT patients, so as to develop prevention and early detection programs, as well as novel treatment strategies, and finally improve prognosis for PSTT patients.

show abstract

Section: Clinical Presentationmentioning

confidence: 99%

Section: Clinical Presentationmentioning

confidence: 99%

See 1 more Smart Citation

A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Gestational choriocarcinoma is the most prevalent GTD. Despite progress in the field of modern reproductive medicine, gestational trophoblastic tumors continue to pose a significant challenges both for diagnosis and treatment owing to their irregularity, broad range of differences in diagnoses, and the uncertainty of detection of the precursor lesions [53]. These factors have fueled the need for extensive research on the development of precise and selective strategies for identifying and treating these tumors through nanotechnology.…”

Section: Pregnancy-related Complications: Ectopic Pregnancy and Gestamentioning

confidence: 99%

Nanotechnology in reproductive medicine: Opportunities for clinical translation

Shandilya

Pathak

Lohiya

et al. 2020

Clin Exp Reprod Med

View full text Add to dashboard Cite

In recent years, nanotechnology has revolutionized global healthcare and has been predicted to exert a remarkable effect on clinical medicine. In this context, the clinical use of nanomaterials for cancer diagnosis, fertility preservation, and the management of infertility and other pathologies linked to pubertal development, menopause, sexually transmitted infections, and HIV (human immunodeficiency virus) has substantial promise to fill the existing lacunae in reproductive healthcare. Of late, a number of clinical trials involving the use of nanoparticles for the early detection of reproductive tract infections and cancers, targeted drug delivery, and cellular therapeutics have been conducted. However, most of these trials of nanoengineering are still at a nascent stage, and better synergy between pharmaceutics, chemistry, and cutting-edge molecular sciences is needed for effective translation of these interventions from bench to bedside. To bridge the gap between translational outcome and product development, strategic partnerships with the insight and ability to anticipate challenges, as well as an in-depth understanding of the molecular pathways involved, are highly essential. Such amalgamations would overcome the regulatory gauntlet and technical hurdles, thereby facilitating the effective clinical translation of these nano-based tools and technologies. The present review comprehensively focuses on emerging applications of nanotechnology, which holds enormous promise for improved therapeutics and early diagnosis of various human reproductive tract diseases and conditions.

show abstract

“…Non-gestational choriocarcinoma is remarkably rare, arising from pluripotent germ cells in the gonads or midline structures, such as the mediastinum [2]. Both of the classifications can have highly varied and atypical clinical presentation [3], most of the time with an uncertain origin [4,5,6].…”

Section: Introductionmentioning

confidence: 99%

When a Differential Diagnosis Is Fundamental: Choriocarcinoma Mimicking Lung Carcinoma

Gasparri

Sedda

Brambilla

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Choriocarcinoma is a rare malignant disease that is usually associated with a gestational event. Lung metastasis with no evident primary origin and choriocarcinoma, which mimics features of non-small-cell lung cancer, might be misdiagnosed as adenocarcinoma or large-cell carcinoma. This is a pivotal clinical concern since the tumor can lead to various symptoms, seriously affecting the quality of life and can escalate rapidly, with a high mortality rate, compared to lung cancer. Methods: We reported a case of a 37-year-old woman with a history of one-year enhancement of beta-human chorionic gonadotropin levels and only a single nodule in the right upper lobe, with no abnormal findings on the gynecological investigation. Then we retrospectively examined all cases treated in the Division of Thoracic Surgery at the European Institute of Oncology in the last twenty years (from 1998 to 2018). Results: This was the first time in our experience that choriocarcinoma presentation was with a single nodule without a gynecological finding. Moreover, the differential diagnosis between lung carcinoma and choriocarcinoma was achieved only after surgical removal. Conclusions: As confirmed by our literature search, precise and expedited differential diagnosis is essential in choriocarcinoma care (both with single or multiple metastases), to successfully remove the tumor and increase the patient’s chances of survival.

show abstract

Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology

Cited by 72 publications

References 51 publications

A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors

A Review on the Pathogenesis and Clinical Management of Placental Site Trophoblastic Tumors

Nanotechnology in reproductive medicine: Opportunities for clinical translation

When a Differential Diagnosis Is Fundamental: Choriocarcinoma Mimicking Lung Carcinoma

Contact Info

Product

Resources

About